Quigley Pharma has announced positive results from a study evaluating their anti-viral compound QR-441(a) in embryonating egg and VERO E6 cell test models.
QR-441(a) was demonstrated as a potential anti-viral agent in reducing Infectious Bronchitis and Newcastle Disease – two pathogens which constantly threaten commercial poultry stocks. Previous in vitro studies have demonstrated QR-441(a) to be a potent antiviral agent against H5N1 (Avian Flu).
“The value of a broad spectrum antiviral addressing multiple viral pathogens in poultry stocks increases the potential utility of the compound for routine commercial application, as well its use in the event of more serious H5N1 (Bird Flu) outbreaks,” said Dr. Richard Rosenbloom of Quigley Pharma.
The study was conducted after receiving industry and veterinary thought leader feedback indicating a need for a well tolerated broad spectrum antiviral agent against these pathogens which continue to threaten poultry industries worldwide.
The preliminary data shows that further study is warranted and that QR-441(a) may have potential in treating and/or preventing Infectious Bronchitis Virus (IBV) and Newcastle Disease Virus (NDV). The company will be preparing experiments to validate the significance of this data in a challenge study in chickens.